We studied eight patients with characteristic features of angioimmunoblastic T cell lymphoma (AILD-TL) associated with more than 25% of large B cells. Polymerase chain reaction (PCR) analysis showed a clonal rearrangement of the T cell receptor (TCR)-gamma chain gene in all cases. One additional case showed a clonal rearrangement of the TCR-beta chain gene by Southern blot hybridization. PCR analysis showed a clonal immunoglobulin rearrangement in three cases presenting with more than 50% of large B cells whereas the other cases had a germline configuration. In 6/8 cases, doublelabeling immunohistochemistry and in situ hybridization demonstrated that Epstein-Barr virus (EBV) was mostly present in the large B cells but also detected in some T cells. We further evaluated the frequency of AILD-TL with more than 25% of large B cells in the 106 cases collected by the French GELA group and found an incidence of 18%. The outcome of these patients did not differ significantly from those with less than 25% of B cells. With this approach we confirm the heterogeneity of AILD-TL features and the possible association with a substantial numbers of CD20 + , EBV + large B cells. We propose to denominate these cases as 'AILD-TL rich in large B cells' and to consider them as a different entity which can be misdiagnosed as a reactive process or as T cell rich B cell lymphoma.
Introduction
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) originally 1 considered as an abnormal immune reaction is now recognized as T cell lymphoma (AILD-TL), [2] [3] [4] characterized by a polymorphic population composed of plasma cells, eosinophils, histiocytes, and lymphoid cells including immunoblasts and atypical lymphoid 'clear' cells, associated with proliferation of post-capillary venules 1 and usually with expanded aggregates of follicular dendritic cells. Most abnormal cells are of T cell phenotype, but a few large B cells are commonly present. 2 Genotypic studies report a clonal rearrangement of T cell receptor (TCR) genes in most cases. [5] [6] [7] Some studies also demonstrate clonal immunoglobulin gene rearrangements (IgH) in some cases of AILD-TL. 5, [8] [9] [10] Rare cases of B cell lymphomas occurring after AILD have been reported [8] [9] [10] and B cell populations in these cases are described as oligoclonal 11 or monoclonal. 5, 6, 8, 9 However, a detailed morphological, immunohistochemical and genotypic analysis of the large B cell component found in AILD-TL has not yet been described.
Epstein-Barr virus (EBV) has been found in 43% of peripheral T cell lymphomas in the Caucasian population. 12 presence in AILD was first reported by Bornkamm et al 13 in 1976 . It was subsequently identified in this disorder [14] [15] [16] [17] affecting both T and/or B cells, 18 but its pathogenic role in lymphoma development is not clear.
Some AILD-TL contain substantial numbers of CD20 + large B cells. In this study, we selected eight cases of AILD-TL containing more than 25% of large B cells and presented a morphological, immunohistochemical and molecular analysis of B and T cell components, the EBV presence and the clinical outcome of the patients. With this approach, we discuss the problem raised by this substantial numbers of CD20
+ large B cells and the presence of EBV in AILD-TL. Our data suggest that AILD could be a heterogeneous group of diseases in the setting of which 'large B cell rich AILD-TL' may be individualized. Furthermore, we have assessed the frequency and the prognosis of this AILD-TL subtype in the French GELA (Groupe d'Etude des Lymphomes de l'Adulte) cooperative study group.
Materials and methods

Patients
Cases were retrieved from the files of the Department of Pathology of Necker Hospital. Lymph node biopsies studied were performed at initial diagnosis. The period of study extended from 1992 to 1999. Cases were selected for the study when they exhibited characteristic histological features of AILD-TL associated with more than 25% of large B cells on lymph node specimens in a preliminary histological and phenotypic examination. Clinical details of patients, treatment and follow-up were obtained from hospital charts and are summarized in Table 1 .
Light microscopy and immunohistochemistry
Histologic sections were prepared from lymph node tissue fixed in 10% formalin, embedded in paraffin and cut at 3 m. These sections were stained with hematoxylin-eosin (H&E), Giemsa and silver stains for histological analysis. All biopsies were reviewed by two different hematopathologists (CL and DC) and the histopathological diagnosis confirmed. The number of large B cells was evaluated separately by these two hematopathologists on H&E, CD20 and CNA42 immunostainings (to avoid the count of large B cells of residual germinal centers). For each case, the percentage of large B cells was evaluated using a semi-quantitative method, after analysis of 300 lymphoid cells at a high power field (×40).
Subsequently, 106 cases of AILD-TL of the GELA French study group, 74 during the period 1987-1993 and 32 since 1993, were also reviewed with the same semi-quantitative method in order to evaluate the frequency and the outcome of patients with more than 25% of CD20 + large B cells. Immunostaining was performed on formalin-fixed and frozen sections by the biotin-avidin peroxidase complex method. The antibodies used included: CD20, CD3, CD2, CD5, CD8, CD30, LMP1 (latent membrane protein of EBV), anti-human dendritic reticulum cell (DRC) anti-kappa and anti-lambda from DAKO; CD4, CD7 and CD56 from Becton Dickinson; Ki67 from Immunotech; TiA-1 from Coulter and CNA-42 (kindly provided by Pr G Delsol, Hô pital Purpan, Toulouse, France).
Epstein-Barr virus (EBV)
In situ hybridization (ISH) study of EBV RNAs was performed on sections cut from formalin-fixed paraffin embedded tissue using the DAKO hybridization kit with a mixture of fluorescein-conjugated deoxyribo-oligonucleotides complementary to the nuclear EBER 1 and 2 (both 30 bases long) (DAKO). A case of infectious mononucleosis served as positive control and negative controls were assayed in the same run. The number of EBER-positive cells in lymph nodes was evaluated by the percentage of coloured nuclei on 300 lymphoid cells. Double-labeling immunohistochemistry and ISH was performed on formalin-fixed paraffin embedded sections. The ISH technique was performed first, the immunohistochemical technique was then performed with the antibodies CD20 and CD43 (DAKO).
Ig/TCR gene rearrangement study by polymerase chain reaction
Each polymerase chain reaction (PCR) was performed on 1 g DNA isolated from the morphologically invaded frozen tissue (lymph nodes) by a standard organic extraction method after digestion with proteinase K. In case 6, DNA extraction was performed from paraffin embedded fixed tissue; 25 sections were dewaxed and digested with proteinase K at 37°C overLeukemia night. DNA was extracted with phenol/chloroform, precipitated and resuspended in 100 l of EDTA-Tris.
Immunoglobulin heavy chain gene rearrangement analysis was performed as previously described by Aubin et al. 19 Two independent PCRs were performed for 35 cycles using either FR1c or FR2 (FR2-56) primers associated with three JH primers (JH1245+JH3+JH6). Fifteen ml of PCR product were electrophoresed on 8% polyacrylamide gels (PAGE) at 140 V for 50 min and visualized under UV illumination after staining of the gel with ethidium bromide (ethidium bromide PCR). The expected size range for FR1c-derived products varies from 330 to 350 bp and for FR2-derived products from 250 to 270 bp. In the paraffin embedded case 6, a semi-nested PCR IgH amplification was performed using the FR1c, FR2 and JH primers as above with an internal JH primer (JH int 2). 20 T cell clonality was analyzed using the T cell receptor (TCR) ␥locus. TCR␥ V-J junctional regions were amplified for 35 cycles in two multiplex PCRs and analyzed by 8% non-denaturing PAGE and ethidium bromide staining (PCR-EB), as described in detail elsewhere. 21 BЈ PCR was done using V␥ family I (V2/3/4/5/7/8) and V10 primers with three J␥ primers (JP, JP1/2 and J1/2); CЈ PCR was done using V9 and V11 primers with the same three J␥ primers. The expected size of V␥I family and V␥9 products was 230-280 bp and 140-170 bp for V␥10 and V␥11. The sensivity of both IgH and TCR analyses is approximately 5%. High-resolution fluorescent TCR␥ 'run-off' analysis was undertaken on an automated DNA fragment analyzer (Perkin Elmer/ABI 373; Roissy, France). Briefly, internal TCR V␥ primers specific for the J␥1/2, JP1/2 and JP segments were labelled with three different fluorophores, and a mixture of the three primers was used in a limited cycle, linear amplification of PCR products. 21 Each PCR experiment included control reactions without DNA, a polyclonal peripheral blood lymphocyte DNA-negative control and clonal positive controls at 100% and 10% diluted into polyclonal DNA.
Southern blot analysis
DNA was available for seven of the eight patients for analysis of IgH and EBV clonality by Southern blotting. Fifteen mg of DNA were digested with BglII or BamHI and HindIII and electrophoresed on 0.8% agarose gels, transferred to a positively charged nylon membrane and hybridized overnight with the following 32 P labeled probes: a 1 kb EcoRI-HindIII IgH JH6 probe, 22 the 1.9 kb XhoI EBV terminal repeat 23 and the 3.1 BamHI BamHIW internal repeat probes. 24 After washing, the membranes were autoradiographed.
Results
Clinical features of eight patients from a single center
Clinical features of the eight patients are given in Table 1 . The male:female ratio was 7:1. The median age was 68.5 years. All patients presented with fever and generalized lymphadenopathy, six had hepatosplenomegaly, half presented with rash, anemia and hypereosinophilia. Hyper-gammaglobulinemia was documented in most patients (7/8), two of them presenting with 20 to 50 g/l and two other patients with up to 50 g/l (cases 6 and 8). Most patients had an advanced Ann Arbor stage disease and extra-nodal involvement occurred in two cases (cavum and bone marrow). Various therapeutic protocols were attempted and the cases with aggressive disease were treated with multiagent anthracyclin containing protocols (detailed in Table 1 ). Four patients died with clinical evidence of active lymphoproliferative disease, three of them because of a septic complication (cases 1, 2 and 8), with a median survival of 3 years. The other four are still alive with active disease, with a median follow-up of 4 years.
Histological and Immunohistochemical features (Table 2)
All eight cases showed diffuse characteristic features of AILD-T cell lymphoma in their lymph node with a marked postcapillary venule proliferation associated with a polymorphic population composed of plasma cells, small lymphocytes, immunoblasts and eosinophils (Figure 1a) . Four cases contained clusters of histiocytes. Angiocentric lesions were observed in 7/8 cases. Clusters of large clear atypical cells were found in all cases (Figure 1b) .
Immunohistochemistry revealed two clear-cut atypical lymphoid populations. The T cell population was clearly predominant in 3/8 cases and represented by small to medium sized lymphoid cells CD3 + (Figure 2a ) with a variable expression of CD2, CD5 and CD7. Scattered cells were stained with anti-CD8, but CD4 + T cells were always predominant. The cytotoxic marker, TiA-1, showed a staining pattern similar to CD8. CD56 was negative on the abnormal cells. Large B cells stained by CD20
+ were either in small clusters or scattered among the other cells (Figure 2b) . In all cases, they were stained both by kappa and lambda light chains. These large B cells constituted more than 25% of the lymphoid cells and in three cases (3, 6 and 8) , represented more than 60% of the lymphoid cells. A high expression of Ki-67 proliferation marker was found independently of the size and/or the morphology of cells (40-70% of cells) (Figure 2c ). CD30 was expressed in six cases on 5-39% of cells ( Figure  2d) . In seven cases, follicular dendritic cells were abundant, with an ill-defined confluent network expansion. (Table 3) TCR␥ analysis:
Molecular genetic findings
The results of TCR gene rearrangement analyses are summarized in Table 3 . Clonal TCR␥ rearrangements were documented by ethidium bromide PCR in six cases (Figure 3 ), whereas one case (No. 8) showed a polyclonal configuration and the case with paraffin embedded material (No. 6) was not analyzed. The bands were of variable, weak to moderate intensity, in keeping with the heterogeneous histological appearance. Fluorescent J␥ run-off analysis confirmed these results and allowed improved evaluation of the number of predominant bands (data not shown). Based on both techniques, four cases demonstrated two predominant peaks and were considered to be clonal, although this was minor in two cases (1 and 7). Two cases (3 and 5) were classified as oligoclonal, based on the presence of at least three predominant peaks. TCR␤ rearrangement was assessed by Southern blotting and hybridization with a TCR C␤ probe on Bg/II and BamHl/HindIII double digests, which allows detection of J␤1 and J␤2 rearrangements respectively. 25, 26 Minor rearranged bands corresponding to J␤1 rearrangements were detected in three cases (3, 4 and 7), one of which also demonstrated a J␤2 rearrangement of comparable intensity ( Figure  4 ). These included cases classified as weakly clonal, clonal and oligoclonal by PCR TCR␥ analysis.
IgH analysis:
IgH chain rearrangement was evaluated by PCR in all eight cases; five revealed a germline configuration, whereas three cases (3, 6 and 8) demonstrated IgH gene rearrangement in FR1c and FR2-56 PCR (Figure 3 ). Southern blot hybridization with an IgH JH6 probe confirmed a minor, bi-allelic rearrangement in both patients with available material but demonstrated only germline bands in five cases which were negative by PCR (Table 3 and Figure 4 ). The three cases with a clonal IgH population corresponded to those with the highest proportion of B lymphocytes. TCR␥ configuration in both cases analyzed was oligoclonal or polyclonal, with the former demonstrating a minor TCR␤ rearrangement by Southern blot.
EBV analysis:
Of the eight patients, six had evidence of EBV in their lymph nodes as detected by ISH (EBER 1,2) . The frequency of labeled nuclei was estimated to be 12.7% (ranging from 2 to 35%) (Figure 5a ). Three cases were also positive by IHC using anti-LMP-1 antibody (Figure 5b ). Double staining performed in cases 6, 7 and 8, identified EBERpositive B cell (Figure 5c ) and T cell (Figure 5d ) phenotype, with a predominance of EBER-positive cells expressing CD20.
Southern blot hybridization with a terminal repeat EBV probe, which allows both viral detection and clonality analysis, was negative in all seven cases tested (Table 3) , including the two cases with a clonal IgH population. In an attempt to determine whether this was due to relative insensitivity, the membranes were re-hybridized with the potentially more sensitive BamHIW probe, which recognises an internal repeat sequence, 23 but all five cases tested were negative.
Leukemia
Frequency and prognosis value of AILD-TL with Ͼ25% of large B cells
Analysis of the frequency of substantial numbers of CD20+ large B cell population (Ͼ25%) in AILD-TL was performed using the GELA French lymphoma protocol study group data base. Out of 1883 patients included in this protocol from 1987 to 1993, 288 (15%) had peripheral T cell lymphomas 27 and among them, 87 (30%) were classified as AILD-TL. In the new GELA French lymphoma protocol beginning in 1993, 32 other AILD-TL were also diagnosed. In 106 of these 119 AILD-TL, B cell immunostaining was available for the semi-quantitative evaluation and clinical data were available for 97/106 patients. Out of these 97 AILD-TL, 79 cases showed less than 25% of large B cells (group A) and 18 cases exhibited more than 25% of large B cells (group B), giving an incidence of 18%. Clinical evolution of both groups of patients in the GELA group was compared. Statistical analysis revealed that there was no difference in overall survival in either group, since 30% of patients in group A and 33.3% of patients in group B were still alive with a median follow-up of 22 months for group A and 17.7 months for group B. A complete remission was obtained in 46.5% in group A and in 64.7% in group B without significant difference between two groups (P = 0.177). This number of large B cells did not appear as a predicting factor for complete remission, or for overall survival in AILD-TL of the GELA group.
Discussion
AILD is a well-defined entity 1 in which T cells represent the majority of abnormal cells intermingled with some large B
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Figure 3
PCR analysis of IgH and TCR␥ rearrangement.
Figure 4
Southern analysis of TCR␤, IgH and EBV.
cells. 5, 7 Genotypic studies 5-7 reveal a clonal TCR gene rearrangement and thus the concept of AILD-T cell lymphoma is currently accepted by the REAL and the WHO classification. [2] [3] [4] In the Western adult population the relative frequency of T cell lymphomas is 15%, of which AILD-TL represent only 9% for centers in the United States and Europe, 3 but 30% for the GELA French group. 27 This discrepancy might be due to a more general consensus in France to diagnose AILD on morphological and clinical criteria and to treat them as T cell lymphoma and so to include them in clinical trials. The frequency of IgH rearrangement in this entity is estimated to be 13%, 6, 10, 11 but only three B cell lymphomas [8] [9] [10] are reported as occurring after AILD-TL. Our cases with typical clinical, morphological and genotypic aspects of AILD-TL were selected because of a substantial number of large B cells (Ͼ25%). Five cases had more than 50% of large B cells. PCR multiplex analysis of TCR␥ genes demonstrated an oligoclonal or clonal population in the majority of cases tested (86%). Three of five cases with an oligoclonal TCR␥ configuration also demonstrated minor TCR␤ rearrangements by Southern blot. Molecular analysis in AILD was until recently based on Southern analysis of TCR␤ and IgH genes. Frizzera 28 compiled data on 107 published cases, 73% of which demonstrated a clonal population at diagnosis. Of these, 93% demonstrated TCR␤ clonality, of which 12% also had an IgH rearrangement. In our series, TCR␥ analysis by PCR allowed identification of a clonal population in 4/5 cases by monoplex denaturing gradient gel electrophoresis (DGGE) analysis 29 and in 4/4 cases analyzed by multiplex ethidium bromide PCR, 30 representing an overall detection rate of 14/16 (87%), including the present cases. Four of these cases were not detected by TCR␤ Southern blot analysis, suggesting that TCR␥ PCR analysis may detect minor clones or oligoclonal cases not picked up by the former technique. AILD-TL in the absence of TCR␤ clonality is also recognized 31 and might be related to a failure to detect oligoclonal TCR␤ populations by Southern blot analysis. 32 A clonal IgH population was observed by PCR and Southern blot analysis in 3/8 cases of our series which were those showing the highest proportion of large B cells (Ͼ60%). The discrepancy between polytypic phenotype of large B cells and clonal IgH expression could be explained by the fact that small clones can emerge from a polyclonal B cell population and only be detected by molecular analysis. The reproducibility of a clonal IgH profile excludes pseudoclonality as an explanation for these divergent results. The incidence of clonal IgH population in our series is higher than the 19% identified by Frizzera 28, 33 but close to the 30% of IgH oligoclones reported by Smith et al 34 and Attygalleet al. 35 Thus, it does not seem that this high incidence of IgH rearrangement could be related to the selection of cases with a high number of B cells in this report, since Smith's series included classical AILD. Interestingly, both IgH clonal cases analyzed demonstrated an oligoclonal or polyclonal TCR␥ configuration. These cases could represent a peculiar subgroup of AILD-TL or alternatively an EBV-associated large B cell lymphoma with abnormal clonal or oligoclonal T cell proliferation. However, our data suggest that TCR␥ and IgH PCR should be performed at diagnosis in all patients, in order to address this issue in a prospective manner.
The presence of both Ig and TCR rearrangements may be explained either by clonal rearrangements in independent B and T cell lymphoid populations respectively, or by illegitimate rearrangement. Thus, TCR␥ and IgH rearrangements could occur in different cells since our study provides morphological and immunophenotypic evidence of separate B and T cell lineage populations.
Our cases bear a resemblance to EBV-positive peripheral T cell lymphomas previously described in the literature. 12, 36 They are especially close to those of Higgins et al 37 who selected their cases as did we, solely on the basis of the presence of a large B cell population in a peripheral T cell lymphoma. However, in contrast to them, our cases are exclusively AILD-TL, the percentage of large B cells is peculiarly high (Ͼ25%) and EBV was present in both B and T cells.
The significance of these B and T cell proliferations, however, remains to be determined. They cannot be diagnosed as T cell rich B cell lymphomas, since clinical and biological data were those of AILD-TL, the atypical T cell population had a TCR rearrangement 38 and the large B cells were polytypic. These cases could be considered as a composite lymphoma defined as two different lymphoid populations involving the same lymph node. Several mechanisms have been proposed 6, 39, 40 to explain the occurrence of multiple clones. First, a peculiar genetic predisposition 39, 40 for mutations that activate an oncogene or inactivate a tumor suppressor gene, which may result in the emergence of two clonal populations. Second, the immune dysregulation status of AILD patients which allows a proliferation of T or B cell clones, with a high probability of overt malignant transformation. 39, 40 Third, factors secreted by the initial neoplastic population (T cells) which could stimulate the development of a second neoplasm. 41 Foss et al 41 described a specific gene expression of tumor necrosis factor-␣ and lymphotoxin by atypical T cells and by some B immunoblasts in AILD-TL. Other studies demonstrated that lymphotoxin is an autocrine growth factor for EBV-transformed human B cell lines or that interleukin-6 is involved in the AILD pathophysiology. [42] [43] [44] [45] These cytokine secretions by T cells might stimulate the development of a clonal B cell population. 8, 9, 41 We can also hypothesize, as in post-transplant lymphoproliferative disorders, 46 that the setting of immune deficiency in
Leukemia AILD leads to a reactivation of latent EBV or favors a primary EBV infection and then an expansion of multiple EBV infected clones. In most of our cases (6/8), EBV was found by ISH, but all cases tested were negative by Southern blot analysis with both terminal and internal repeat probes. These data are not in keeping with the literature, in which the majority of AILD cases analyzed by Southern were found to be EBV-positive. 14, 18, 37 The sensitivity of this technique with an LTR probe is 1-5% in our hands (data not shown). These discrepancies suggest that the negativity is partly due to the relative insensitivity of Southern blot technique, but also that EBV-positive cells are likely to result from polyclonal infection, which will further reduce the sensitivity of their detection with a terminal repeat probe, since the differently sized DNA fragments will migrate in a heterogeneous manner. It is noteworthy that one of the IgH clonal cases was EBV-negative, suggesting that the appearance of a B lymphoid clone can be independent of EBV reactivation. Furthermore, double labeling staining confirmed the EBV presence in B and T cells and it is tempting to speculate that EBV is involved in B or T cell transformation. However, we propose, like Weiss et al, 7 rather that EBV is a consequence of immunosuppression status and may play a role in a clonal expansion but is not the only causal factor of B cell clonal transformation. Secondary genetic events 39 and abnormal secretion of cytokines 41, 43 could also be implicated in this process. The diagnostic implications of our findings are apparent since in 5/8 cases the diagnosis of AILD-TL could have been missed because of the large amount of B cells as in the Higgins et al 37 series. Concerning the clinical features and prognosis of these peculiar cases it is likely that a worse course is related, especially when the B cell component is predominant or monoclonal. We cannot confirm this hypothesis with the short follow-up of our cases. Statistical analysis of the 97 homogeneous treated cases of AILD-TL of the GELA group by comparing the cases with more than 25% of large B cells with other AILD-TL showed that B cell numbers did not appear as a predicting factor of complete remission, nor for overall survival in AILD-TL. A prospective study is nevertheless warranted to determine whether or not B cell numbers have a prognostic impact on evolution towards a large B cell lymphoma. Furthermore, this AILD-TL subgroup may require specific therapy such as anti-CD20 monoclonal antibody and/or antiviral therapy as in post-transplant lymphoproliferations. 46 In conclusion, our study supports the concept that AILD-TL could be a heterogeneous T cell lymphoproliferative entity, sometimes associated with an important large B cell component (18% in the GELA protocol), and an EBV infection in which genotypic studies can occasionally reveal a double T and B clonal population. Even though with current therapeutic protocols the number of large B cells has no impact on survival, this peculiar form could be considered as a different AILD-TL subtype, and hence might be classified as 'large B cell rich AILD-TL'. This entity seems to correspond to a dynamic process associated with an immunoregulation defect in which lymphoid cells are able to proliferate by several synergic mechanisms, resulting in a clonal expansion of both B and T cells.
